Phase II Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or RefractoryAcute Lymphoblastic Leukemia
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 26 Oct 2018 Status changed from active, no longer recruiting to completed.
- 01 Aug 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
- 01 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.